Quinazoline derivatives as antitumor agents
CA 2465068 A1 · Owner: Astrazeneca Ab · Inventors: Bradbury, Robert Hugh; Pass, Martin; Hennequin, Laurent Francois Andre
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention concerns quinazoline derivatives of Formula (I); wherein each of Q1, Z, R1 and Q2 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the prevention or treatment of tumours which are sensitive to inhibition of erbB receptor tyrosine kinases.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 31, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 31, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 31, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.